Literature DB >> 16488547

Hormone therapy and cognitive function: is there a critical period for benefit?

P M Maki1.   

Abstract

The large majority of women receiving hormone therapy initiate therapy early in life for the treatment of menopausal symptoms. However, the Women's Health Initiative Memory Study, the only randomized clinical trial to date on hormone therapy and dementia, was carried out in women age 65 and older. That trial provided important insights into the detrimental effects of hormone therapy on dementia in women initiating later in life. The generalizability of those findings to the typical hormone therapy user who initiates earlier in life is unknown. To address this important issue, this review focuses on observational trials of hormone therapy and dementia risk, randomized clinical trials of hormone therapy and cognitive function, and basic science studies. These lines of research provide suggestive, but not definitive, evidence that early initiation of hormone therapy may provide cognitive benefits, particularly to verbal memory and other hippocampally mediated functions. Other forms of hormone therapy, other cognitive domains, and cyclic hormone regimens may not conform to this "critical period hypothesis." Further research is needed to test the validity and limits of this hypothesis.

Entities:  

Mesh:

Year:  2006        PMID: 16488547     DOI: 10.1016/j.neuroscience.2006.01.001

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  68 in total

Review 1.  Estrogen neuroprotection and the critical period hypothesis.

Authors:  Erin Scott; Quan-guang Zhang; Ruimin Wang; Ratna Vadlamudi; Darrell Brann
Journal:  Front Neuroendocrinol       Date:  2011-11-04       Impact factor: 8.606

2.  Estradiol treatment altered anticholinergic-related brain activation during working memory in postmenopausal women.

Authors:  Julie A Dumas; Amanda M Kutz; Magdalena R Naylor; Julia V Johnson; Paul A Newhouse
Journal:  Neuroimage       Date:  2012-01-12       Impact factor: 6.556

Review 3.  Perimenopause and cognition.

Authors:  Gail A Greendale; Carol A Derby; Pauline M Maki
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

Review 4.  A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.

Authors:  Erin E Sundermann; Pauline M Maki; Jeffrey R Bishop
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

Review 5.  Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline.

Authors:  Karyn M Frick
Journal:  Behav Neurosci       Date:  2012-02       Impact factor: 1.912

6.  Estradiol-induced object memory consolidation in middle-aged female mice requires dorsal hippocampal extracellular signal-regulated kinase and phosphatidylinositol 3-kinase activation.

Authors:  Lu Fan; Zaorui Zhao; Patrick T Orr; Cassie H Chambers; Michael C Lewis; Karyn M Frick
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

Review 7.  Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women.

Authors:  John H Morrison; Roberta D Brinton; Peter J Schmidt; Andrea C Gore
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

Review 8.  Estrogen therapy and cognition: a review of the cholinergic hypothesis.

Authors:  Robert B Gibbs
Journal:  Endocr Rev       Date:  2009-12-17       Impact factor: 19.871

Review 9.  Premature menopause and risk of neurological disease: basic mechanisms and clinical implications.

Authors:  Erin L Scott; Quan-Guang Zhang; Ratna K Vadlamudi; Darrell W Brann
Journal:  Mol Cell Endocrinol       Date:  2014-01-22       Impact factor: 4.102

10.  Neuroprotective actions of selective estrogen receptor modulators.

Authors:  Lydia L DonCarlos; Iñigo Azcoitia; Luis M Garcia-Segura
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.